Genprex, Inc. (GNPX)
- Previous Close
0.3820 - Open
0.4000 - Bid 0.4210 x 100
- Ask 0.4286 x 100
- Day's Range
0.3900 - 0.4290 - 52 Week Range
0.2810 - 16.9600 - Volume
616,588 - Avg. Volume
428,809 - Market Cap (intraday)
1.109M - Beta (5Y Monthly) -0.57
- PE Ratio (TTM)
-- - EPS (TTM)
-15.6000 - Earnings Date Nov 12, 2024 - Nov 18, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
8.75
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. Its three lung cancer clinical programs have received a Fast Track Designation from the FDA for the treatment of that patient population, and SCLC program has received an FDA Orphan Drug Designation. The company's diabetes gene therapy comprises of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, its GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body's immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
www.genprex.comRecent News: GNPX
View MorePerformance Overview: GNPX
Trailing total returns as of 9/23/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GNPX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GNPX
View MoreValuation Measures
Market Cap
988.82k
Enterprise Value
-1.47M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.23
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
0.18
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-145.94%
Return on Equity (ttm)
-318.88%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-26.14M
Diluted EPS (ttm)
-15.6000
Balance Sheet and Cash Flow
Total Cash (mrq)
2.46M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-12.45M
Research Analysis: GNPX
View MoreCompany Insights: GNPX
GNPX does not have Company Insights